Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

NCT01160718 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: fulvestrant
DRUG: selumetinib

Sponsor

Swiss Cancer Institute